- Investing Ideas
- /
- Hong Kong Pharmaceuticals & Biotech Strong Balance Sheet Stocks
Hong Kong Pharmaceuticals & Biotech Strong Balance Sheet Stocks
Results
92
Strong Balance Sheet Stocks: companies with a Health score of at least 4, ordered by Health score.
92 companies
TYK Medicines
Market Cap: HK$6.0b
A clinical-stage biopharmaceutical company, research, development and commercialization of pharmaceutical products.
2410
HK$15.82
7D
0%
1Y
-48.5%
Beijing Luzhu Biotechnology
Market Cap: HK$4.9b
A biotechnology company, focuses on the research and development, production, and sale of human vaccines and therapeutic biologics to prevent and control infectious diseases, and treat cancer and autoimmune diseases in Mainland China.
2480
HK$24.86
7D
1.4%
1Y
18.4%
Ascentage Pharma Group International
Market Cap: HK$27.3b
A clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.
6855
HK$74.50
7D
-3.1%
1Y
92.3%
BioDlink International
Market Cap: HK$1.7b
An investment holding company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in Mainland China and internationally.
1875
HK$2.26
7D
2.3%
1Y
11.3%
Biocytogen Pharmaceuticals (Beijing)
Market Cap: HK$11.8b
A biotechnology company, engages in the research and development of novel antibody-based drugs in the People’s Republic of China, the United States, and internationally.
2315
HK$29.50
7D
7.1%
1Y
372.0%
XtalPi Holdings
Market Cap: HK$53.3b
An investment holding company, engages in the provision of robotics and drug discovery solutions in Mainland China, the United States, and internationally.
2228
HK$12.38
7D
16.6%
1Y
-1.0%
Shanghai Junshi Biosciences
Market Cap: HK$43.8b
A biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China.
1877
HK$30.92
7D
-5.6%
1Y
153.0%
Frontage Holdings
Market Cap: HK$2.5b
A contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies.
1521
HK$1.25
7D
-8.8%
1Y
71.2%
Luye Pharma Group
Market Cap: HK$13.4b
Develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally.
2186
HK$3.36
7D
-9.4%
1Y
5.3%
RemeGen
Market Cap: HK$63.5b
A biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States.
9995
HK$107.00
7D
0%
1Y
708.2%
Kintor Pharmaceutical
Market Cap: HK$1.1b
A clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology in the People’s Republic of China.
9939
HK$2.48
7D
-8.1%
1Y
150.5%
SSY Group
Market Cap: HK$8.7b
An investment holding company, researches, develops, manufactures, trades in, and sells various pharmaceutical products to hospitals and distributors in the People’s Republic of China and internationally.
2005
HK$2.96
7D
-1.7%
1Y
-24.3%
Akeso
Market Cap: HK$125.0b
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide.
9926
HK$135.70
7D
3.6%
1Y
112.2%
Austar Lifesciences
Market Cap: HK$548.5m
An investment holding company, engages in the provision of integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally.
6118
HK$1.07
7D
-5.3%
1Y
91.1%
Biosino Bio-Technology and Science Incorporation
Market Cap: HK$125.9m
Manufactures, sells, and distributes in-vitro diagnostic reagents in Mainland China.
8247
HK$0.87
7D
-10.3%
1Y
27.9%
Tianda Pharmaceuticals
Market Cap: HK$354.8m
Engages in the research and development, manufacture, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hong Kong, and Australia.
455
HK$0.17
7D
4.4%
1Y
-30.1%
CanSino Biologics
Market Cap: HK$16.2b
Develops, manufactures, and commercializes vaccines in the People’s Republic of China.
6185
HK$48.90
7D
-7.0%
1Y
123.3%
Laekna
Market Cap: HK$5.4b
An investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis in the People’s Republic of China, the United States of America, and South Korea.
2105
HK$12.82
7D
-6.3%
1Y
148.4%
AIM Vaccine
Market Cap: HK$5.1b
Engages in the research and development, manufacture, and sale of vaccine products for human use in the People’s Republic of China.
6660
HK$4.14
7D
-7.2%
1Y
-7.0%
Cutia Therapeutics
Market Cap: HK$3.1b
An investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong.
2487
HK$8.79
7D
-9.4%
1Y
-42.3%